SH

Stephen Hansen

Person

Heard in 1 episode across 1 show since Oct 2026

Stephen Hansen is a life sciences finance journalist and lead finance writer at BioCentury, covering biotechnology markets, companies, and investment trends.

Episodes

1
across 1 show

First heard

Oct 2026

Guest appearances

1

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Nov 20250
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20260
Sep 20260
Oct 20261

What Stephen Hansen has said on podcasts

7 statements

  1. on Public therapeutics company acquisitionsNegativeOct 13, 2026· BioCentury This Week

    Large public therapeutics acquisitions have paused since mid-July.

    “the last really big public therapeutics company acquisition was mid-July. It's been almost three months since then.”

    Listen at 2:02

    Open the episode · Ep. 392 - Biotech markets: Pause before the storm?
  2. on ModernaPositiveOct 13, 2026· BioCentury This Week

    Moderna reported positive Phase 3 adjuvant melanoma cancer data.

    “the Moderna positive phase three cancer data in adjuvant melanoma”

    Listen at 3:07

    Open the episode · Ep. 392 - Biotech markets: Pause before the storm?
  3. on Biotech market activityMixedOct 13, 2026· BioCentury This Week

    Biotech activity will remain quiet in Q4 before recovering early next year.

    “the thought is that it's going to be a pretty quiet fourth quarter as well and then hopefully things will pick up again at the start of the year”

    Listen at 5:43

    Open the episode · Ep. 392 - Biotech markets: Pause before the storm?
See all 7 statements →

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

1 episode featuring Stephen Hansen, newest first